Working… Menu

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b (ADHERENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03408093
Recruitment Status : Completed
First Posted : January 23, 2018
Last Update Posted : June 21, 2018
Information provided by (Responsible Party):

Brief Summary:
The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) who had more than 6 months in treatment.

Condition or disease Intervention/treatment
Multiple Sclerosis Drug: Interferon beta-1b (Betaseron, BAY86-5046)

Layout table for study information
Study Type : Observational
Actual Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
Actual Study Start Date : February 3, 2009
Actual Primary Completion Date : March 30, 2010
Actual Study Completion Date : March 30, 2010

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Interferon beta-1b
Patients with CIS, RRMS or SPMS who had more than 6 months in treatment
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.

Primary Outcome Measures :
  1. Self-reported adherence to INFb-1b in the previous four weeks assessed by Morisky-Green (MG) test [ Time Frame: Four weeks just before baseline visit ]

Secondary Outcome Measures :
  1. Demographic data [ Time Frame: At baseline ]
    Age, sex, marital status, education level, employment status

  2. Number of patients with MS diagnosis [ Time Frame: At baseline ]
  3. Age at first episode and at diagnosis [ Time Frame: At baseline ]
  4. Time since last relapse [ Time Frame: At baseline ]
  5. Assessment of general health status using data from a questionnaire or from their clinical history collected by the investigator team [ Time Frame: At baseline ]
  6. Expanded Disability Status Scale (EDSS) to assess the degree of disability caused by MS [ Time Frame: At baseline ]
    The EDSS quantifies the disability in eight functional systems (FS) and allows neurologists to assign a level of Functional System in each of them caused by multiple sclerosis.

  7. Number of patients with adverse events during the last month [ Time Frame: Four weeks just before baseline visit ]
  8. Clinical setting characteristics like existence of MS unit [ Time Frame: At baseline ]
    The existence of Multiple Sclerosis Unit was evaluated bearing in mind if the hospital had or had not available a Multiple Sclerosis Unit into the hospital Neurology Department.

  9. Time on INFb-1b therapy [ Time Frame: At baseline ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study included patients who had been on interferon beta-1b for more than 6 months and who agreed to participate in this study.

Inclusion Criteria:

  • Patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) or patients with a first outbreak or clinically isolated syndrome (CIS) that carry more than 6 months in treatment with interferon beta-1b

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03408093

Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT03408093     History of Changes
Other Study ID Numbers: 2008/01880
First Posted: January 23, 2018    Key Record Dates
Last Update Posted: June 21, 2018
Last Verified: June 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Interferon beta-1b (INFb-1b)
Multiple Sclerosis (MS)
Relapsing-remitting MS (RRMS)
Secondary progressive MS (SPMS)
Clinically isolated syndrome (CIS)
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Interferon beta-1b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic